

CALL FOR RESEARCH

PROPOSALS

RTFCCR / LLS PATIENT-FOCUSED IMMUNOTHERAPY RESEARCH GRANT FOR BLOOD CANCER

LOI APPLICATION DEADLINE:

January 25, 2016

Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and The Leukemia & Lymphoma Society (LLS) are partnering for the first time to launch an international competitive grant to advance breakthrough immunotherapies for blood cancers. *This grant is focused on addressing four critical topics and is endowed with a total of USD 1.8 million; 3 grants will be awarded up to USD 600,000 each.*

All researchers are encouraged to submit their project, which should include a clinical trial and address any of the topics below:

- ◆ Characterize the status of the immune system with the purpose of stratifying patients on conventional therapies or emerging immunotherapies for the treatment of blood cancers
- ◆ Development of novel immunotherapeutics for blood cancer
- ◆ Development of repurposed agents that engage the immune system
- ◆ Examine the quality of life improvements during or after immunotherapy for the treatment of blood cancers

Letters of intent (LOI) must be submitted electronically via the grant system at <https://lls.fluxx.io> by January 25, 2016. Only the most promising research projects with the highest potential for patient impact will be invited to submit a full grant application, which must be received by March 15, 2016. Winners will be announced by June 30, 2016.



For application
information:

Eveline Mumenthaler, Director, Rising Tide Foundation
eveline.mumenthaler@risingtide.ch | www.risingtide-ccr.org

Lee Greenberger, Chief Scientific Officer, The Leukemia & Lymphoma Society
lee.greenberger@lls.org | www.lls.org

RISING TIDE
FOUNDATION FOR
CLINICAL CANCER RESEARCH



LEUKEMIA &
LYMPHOMA
SOCIETY®

fighting blood cancers

**someday
is today**®

CALL FOR RESEARCH

PROPOSALS

RTFCCR / LLS PATIENT-FOCUSED IMMUNOTHERAPY RESEARCH GRANT FOR BLOOD CANCER

LOI APPLICATION DEADLINE:

January 25, 2016

APPLICANT REQUIREMENTS:

- Must hold an MD, PhD, or equivalent degree, and work in non-profit organizations, such as universities, colleges, hospitals or laboratories.
- Must maintain an independent research or academic position.
- Applications are accepted from any nation where meaningful grant oversight is possible.
- Applications from non-academic facilities and post doctoral positions are not eligible.

ELIGIBLE FOCUS OF PROPOSALS:

- Contain novel, unpublished findings.
- Clinical trials that demonstrate patient-centered approach (e.g., benefits, QoL issues, etc.).
- Grant activation is expected within three months after award notification.
- Submission of advanced or fully developed research protocols are recommended.
- Preference is given to international collaborative projects utilizing methods that accelerate clinical benefit (e.g., use effective, novel clinical trial designs, such as biomarker-driven patient selection, pharmacodynamic endpoint assessment, etc.).
- Extensions of conventional or traditional chemotherapy such as phase III/IV trials will not be supported.
- Applications that have solely basic and pre-clinical research without an anticipated clinical trial or outcome will not be considered. Placebo-only agent arms should be avoided.
- No more than 40% of direct cost may be requested for the salary and fringe benefit expenses of professional staff; travel costs are not supported.

About RTFCCR:

Rising Tide Foundation for Clinical Cancer Research (RTFCCR) is a private non-profit organization established in 2010 in Switzerland. It actively seeks the brightest minds in science and medicine, and collaborates with a global network of research excellence centers to fund novel, highly promising clinical trials and translational research that can improve patients' survival and quality of life within 3 years or less.

About LLS:

The Leukemia & Lymphoma Society (LLS) is a U.S. based 501 c-3 founded in 1949. As the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services, LLS's mission is to cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

